ttps://www.clinicaltrials.gov/ct2/show/NCT01663402?term=praluent+and+outcome&rank=1
Odissey Outcome completed on January 23, 2018. So, Schleifer LIED (purposely or not, or to protect presentation-publication??? whatever, it is still lied) in first remarks,...and Yan. in responding to CHD death hypothesis:
seekingalpha.com
Len :"Turning now to Praluent, we will be presenting data from the 18,000 patient ODYSSEY cardiovascular outcomes study on March 10 at the meeting of the American College of Cardiology. To be clear, the study has not yet been unblinded. We believe that the PCSK9 inhibitor class holds tremendous promise despite the slow initial uptake, and we look forward to providing you with additional information after the outcomes data become available."
Ying Huang - Bank of America Merrill Lynch
Hi. Good morning. Thanks for taking the questions. First one maybe on ODYSSEY OUTCOMES study since it's going to read out soon. Your competitor Repatha did not show any benefit in cardiovascular mortality. So how important do you think it will be for your drug Praluent to show that benefit? And then secondly, can you talk about life-cycle management strategy for EYLEA now that it seems Ang2 is not going to be going forward into Phase 3? Thank you.
George Damis Yancopoulos - Regeneron Pharmaceuticals, Inc.
Sure. So just to cover ODYSSEY, I don't think that it's worth, Ying, speculating too much on what this result or what that result might be since we don't know the results, but we'll know the results by the March 10 ACC event. So I think we'll all look at the events together basically and we'll be able to judge then. About EYLEA.
Now, we have OLD SUCKER, Goldstein, (as he did took any and every opportunity IN PAST to benefit from INSIDERS sale shares from options exercise) who was this time bit scary, so he sold only 1000 shares.
secfilings.nasdaq.com
Will be interesting to see when they will report/release Top-line results?? Next week? Or, Friday, March 09? In past, ON AXOKINE P3 failure, they reported results 6 hr after (night before 6 am PR release) it was reported in per-view journal that Axokine has NEUTRALIZING antibody in +90% subjects treated with drug. Definitely, I would not be surprise IF history repeat itself! |
